ARRY-382 is a small molecule and orally available inhibitor designed to target colony-stimulating factor-1 receptor (CSF1R, also known as cFMS). It functions by binding to and inhibiting cFMS tyrosine kinase activity, thereby disrupting CSF-1-mediated signaling that is implicated in tumor cell proliferation and macrophage regulation.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 1313407-95-2
Afatinib D6
active pharmaceutical ingredient
Gadodiamide
gadolinium-based MRI contrast agent
Arbidol
antiviral active pharmaceutical ingredient
Ethyl 6-bromo-5-hydroxy-1-methyl-2-((phenylthio)methyl)-1H-Indole-3-carboxylate
antiviral active pharmaceutical ingredient
N-[3-cyclopropyl-1-[(6-methyl-2-pyridinyl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide
JUPOTOIJLKDAPF-UHFFFAOYSA-N
CC1=NC(=CC=C1)CN2C3=CC=CC(=C3C(=N2)C4CC4)NC(=O)C5=CN=C6N5C=CC(=C6)OCCN7CCN(CC7)C